Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
- Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
- Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
- Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
- Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
- Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
- Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
- Will New Drug Makers Dominate Domestic Biosimilars Market?
December 26, 2011
- Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
- “Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
- Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
- Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
- Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
- Pinning Hope on Academia in Seeking a Radical Cure for AD
October 10, 2011
- New Ideas Needed to Address “Insurance Lag” for GE Drug Makers That Submit Applications Based on Info. in Public Domain
October 3, 2011
- Discussions on Amendment of PAL Now in Final Stages
October 3, 2011
- Korosho Revises GL for Drafting, Distributing Drug Safety Information
September 5, 2011
- Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
August 29, 2011
- Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
August 8, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…